Patients’ perception of proton pump inhibitors use and their risks

Table 1 Demographic data of study participants

Variable	Values
Total participants	3000 (100%)
Language distribution	Hebrew 73.8%, Arabic 16%, Russian 10.2%
Sex	Male 46.1%, female 51.9%, other/NR 1.9%
Age groups	18-30: 17%, 31-45: 21.7%, 46-60: 20.1%, 61-75: 21.3%, > 76: 19.9%
Education	None 49%, primary 15.1%, secondary 34.6%, BA 31.3%, postgrad 14.1%
Medical conditions	GERD 16.3%, ulcer 17.1%, gastritis 16.7%, liver/kidney 15.7%, other 17.3%
PPI duration	< 1 month: 11.1%, 1-6 months: 29.4%, 6-12 months: 28.8%, > 1 year: 30.7%
PPI type	Dex 2.3%, eso 23.4%, lan 24.2%, ome 272%, pan 22.9%

BA: Bachelor of Arts; Dex: Dexlansoprazole; eso: Esomeprazole; GERD: Gastroesophageal reflux disease; lan: Lansoprazole; NR: Not reported; ome: Omeprazole; pan: Pantoprazole; PPI: Proton pump inhibitor.

Table 2 Patients’ perception of gastric cancer risk with proton pump inhibitor

PPI type	Risk perceived (%)	n
Dexlansoprazole	18.9	14/74
Esomeprazole	22.8	164/719
Lansoprazole	24.1	172/715
Omeprazole	24.0	198/823
Pantoprazole	26.5	177/669

PPI: Proton pump inhibitor.

Table 3 Self-reported adverse effects of proton pump inhibitors

Side effect	Respondents (%)
Abdominal pain	36.5
B12 deficiency	24.8
Fatigue	20.0
Iron deficiency	15.3
Infections	9.3
Renal issues	4.6
Constipation	31.3
None	12.5

Table 4 Quality of life and anxiety by proton pump inhibitor type

PPI type	Improved QoL (%)	Anxiety (%)
Omeprazole	42%	18%
Esomeprazole	40%	17%
Lansoprazole	61%	9%
Pantoprazole	44%	16%
Dexlansoprazole	47%	14%

PPI: Proton pump inhibitor; QoL: Quality of life.